{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:11:57Z","timestamp":1790507517797,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00359","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:24:31Z","timestamp":1557188671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Willem Jan","family":"van Weelden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon F. A. G.","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ENITEC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. A.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-319-42542-9_7","article-title":"Obesity and endometrial cancer","volume":"208","author":"Shaw","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T","article-title":"Overweight as an avoidable cause of cancer in Europe","volume":"91","author":"Bergstrom","year":"2001","journal-title":"Int J Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1079\/PNS200068","article-title":"Energy balance and cancer: the role of sex hormones","volume":"60","author":"Key","year":"2001","journal-title":"Proc Nutr Soc."},{"key":"B5","first-page":"1531","article-title":"Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review","volume":"11","author":"Kaaks","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/aje\/kwq300","article-title":"Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition","volume":"172","author":"Allen","year":"2010","journal-title":"Am J Epidemiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/JME-15-0310","article-title":"Aromatase expression and regulation in breast and endometrial cancer","volume":"57","author":"Zhao","year":"2016","journal-title":"J Mol Endocrinol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4419-0489-8_8","article-title":"Precursor lesions of endometrial carcinoma","volume-title":"Blaustein's Pathology of the Female Genital Tract","author":"Ellenson","year":"2011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int J Gynaecol Obstet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/IJWH.S40942","article-title":"Past, present, and future of hormonal therapy in recurrent endometrial cancer","volume":"6","author":"Carlson","year":"2014","journal-title":"Int J Women's Health."},{"key":"B13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJM196102022640503","article-title":"Progestational agents in the treatment of carcinoma of the endometrium","volume":"264","author":"Kelley","year":"1961","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1210\/edrv.20.3.0371","article-title":"Selective estrogen receptor modulators: clinical spectrum","volume":"20","author":"Cosman","year":"1999","journal-title":"Endocr Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/gme.0b013e318223bbf4","article-title":"Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass","volume":"19","author":"Goldstein","year":"2012","journal-title":"Menopause."},{"key":"B18","first-page":"4309","article-title":"Fulvestrant in postmenopausal women with advanced breast cancer","volume":"9","author":"Bross","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer?","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00404-015-3974-9","article-title":"Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma","volume":"293","author":"Bogliolo","year":"2016","journal-title":"Arch Gynecol Obstet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17425255.2016.1244264","article-title":"The role of fulvestrant in endometrial cancer","volume":"13","author":"Bogliolo","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B23","unstructured":"Study Quality Assessment Tools"},{"key":"B24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/09296174.2013.799918","article-title":"Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods","volume":"20","author":"Wallis","year":"2013","journal-title":"J Quant Linguist."},{"key":"B25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0360-3016(92)90676-9","article-title":"Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma","volume":"24","author":"Rose","year":"1992","journal-title":"Int J Rad Oncol Biol Phys."},{"key":"B26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1006\/gyno.1996.0074","article-title":"Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study","volume":"60","author":"Pinelli","year":"1996","journal-title":"Gynecol Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0090-8258(03)00149-5","article-title":"Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a gynecologic oncology group study","volume":"89","author":"Covens","year":"2003","journal-title":"Gynecol Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejogrb.2009.02.005","article-title":"The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma","volume":"144","author":"Dahhan","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ygyno.2018.03.008","article-title":"Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: a multicenter review","volume":"149","author":"Beck","year":"2008","journal-title":"Gynecol Oncol."},{"key":"B31","first-page":"83","article-title":"Tamoxifen treatment of advanced endometrial carcinoma","volume":"4","author":"Hald","year":"1983","journal-title":"Eur J Gynaecol Oncol."},{"key":"B32","first-page":"327","article-title":"Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate","volume":"71","author":"Kline","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"B33","first-page":"323","article-title":"Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri\u2013a phase II study of toremifene","volume":"10","author":"Horvath","year":"1990","journal-title":"Anticancer Res."},{"key":"B34","year":"2016","journal-title":"Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer\/Endometrial Cancer"},{"key":"B35","year":"2018","journal-title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer"},{"key":"B36","year":"2019","journal-title":"Hormone Receptor Positive Endometrial Carcinoma Treated by Dual mTORC1\/mTORC2 Inhibitor and Anastrozole (VICTORIA)"},{"key":"B37","year":"2019","journal-title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors"},{"key":"B38","year":"2020","journal-title":"Open-Label PHASE 1b Study of ARQ 092 in Combination With Anastrozole."},{"key":"B39","year":"2020","journal-title":"A Phase 2 Study of LY3023414 and Abemaciclib With or Without Letrozole in Endometrial Cancer"},{"key":"B40","year":"2020","journal-title":"Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium\/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer"},{"key":"B41","year":"2021","journal-title":"Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer"},{"key":"B42","year":"2021","journal-title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0090-8258(81)80003-0","article-title":"Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma","volume":"11","author":"Bonte","year":"1981","journal-title":"Gynecol Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0028-2243(84)90071-6","article-title":"Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma","volume":"17","author":"Rendina","year":"1984","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0090-8258(88)80012-X","article-title":"Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status","volume":"31","author":"Ayoub","year":"1988","journal-title":"Gynecol Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0090-8258(89)90839-1","article-title":"Tamoxifen therapy in advanced\/recurrent endometrial carcinoma","volume":"32","author":"Quinn","year":"1989","journal-title":"Gynecol Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A Phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00000421-200102000-00007","article-title":"Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group study (E4882)","volume":"24","author":"Pandya","year":"2001","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"B49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J Clin Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0090-8258(03)00203-8","article-title":"A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer","volume":"90","author":"McMeekin","year":"2003","journal-title":"Gynecol Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1048-891X.2004.14419.x","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - A study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int J Gynecol Cancer."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: a Gynecologic Oncology Group study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynakologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1471-2407-14-68","article-title":"Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)","volume":"14","author":"Lindemann","year":"2014","journal-title":"BMC Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00428-003-0947-3","article-title":"Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification","volume":"444","author":"Lax","year":"2004","journal-title":"Virchows Arch."},{"key":"B61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14737140.2016.1191949","article-title":"Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?","volume":"16","author":"Slowik","year":"2016","journal-title":"Expert Rev Anticancer Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1634\/theoncologist.2016-0062","article-title":"Chemotherapy for endometrial cancer in adjuvant and advanced disease settings","volume":"21","author":"Bestvina","year":"2016","journal-title":"Oncologist."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.04.012","article-title":"GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate\/tamoxifen, PT) in women with advanced, persistent or recurrence endometrial carcinoma (EC): a GOG Foundation study","author":"Slomovitz","year":"2018","journal-title":"SGO 49th Annual Meeting on Women's Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"84579","DOI":"10.18632\/oncotarget.19961","article-title":"Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials","volume":"8","author":"MacKay","year":"2017","journal-title":"Oncotarget."},{"key":"B65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"14","author":"Lentz","year":"1996","journal-title":"J Clin Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J Clin Oncol."},{"key":"B67","first-page":"1140","article-title":"Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen","volume":"41","author":"Mortel","year":"1981","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0002-9378(84)90187-X","article-title":"Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia","volume":"149","author":"Carlson","year":"1984","journal-title":"Am J Obstet Gynecol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1634\/theoncologist.12-6-636","article-title":"Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy","volume":"12","author":"Tacca","year":"2007","journal-title":"Oncologist."},{"key":"B70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/IGC.0b013e31820575f5","article-title":"Evolution in endometrial cancer: evidence from an immunohistochemical study","volume":"21","author":"Vandenput","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0134969","DOI":"10.1371\/journal.pone.0134969","article-title":"Endometrial endometrioid carcinoma metastases show decreased ER-Alpha and PR-A expression compared to matched primary tumors","volume":"10","author":"Bartosch","year":"2015","journal-title":"PLoS ONE."},{"key":"B72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00259-010-1589-8","article-title":"Functional oestrogen receptor alpha imaging in endometrial carcinoma using 16alpha-[(1)(8)F]fluoro-17beta-oestradiol PET","volume":"38","author":"Tsujikawa","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S1470-2045(13)70292-4","article-title":"PET imaging of oestrogen receptors in patients with breast cancer","volume":"14","author":"van Kruchten","year":"2013","journal-title":"Lancet Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","article-title":"Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways","volume":"74","author":"Verhaegh","year":"2014","journal-title":"Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"E591","DOI":"10.1210\/jc.2011-2994","article-title":"Overexpression of 17beta-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17beta-estradiol","volume":"97","author":"Cornel","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2016.11.030","article-title":"High mRNA levels of 17beta-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer","volume":"442","author":"Cornel","year":"2017","journal-title":"Mol Cell Endocrinol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:24:36Z","timestamp":1557188676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":76,"alternative-id":["10.3389\/fonc.2019.00359"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00359","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"article-number":"359"}}